Immune-Based Therapies for Sarcoma by Pollack, Seth M. et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2011, Article ID 438940, 7 pages
doi:10.1155/2011/438940
Review Article
Immune-BasedTherapies for Sarcoma
SethM. Pollack,ElizabethT. Loggers,EveT. Rodler,CassianYee,andRobin L.Jones
Fred Hutchinson Cancer Research Center, University of Washington, 825 Eastlake Avenue East, G3630, Seattle, WA 98109-1023, USA
Correspondence should be addressed to Robin L. Jones, rjones@seattlecca.org
Received 15 October 2010; Accepted 3 January 2011
Academic Editor: Stephen Lessnick
Copyright © 2011 Seth M. Pollack et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Immunotherapy has shown promise in a number of tumor types, but its exact role in sarcoma remains to be deﬁned. Advanced
bone and soft tissue sarcomas are challenging diseases to treat with an unmet need for eﬀective systemic therapy. Previous reports
have suggested that immune-based treatments may be eﬀective in sarcoma, but such approaches have not yet become part of
standardclinicalpractice.Anumberofsarcomasubtypesexpresstargetsknownascancertestisantigensandhencemaybeexcellent
targets for immunotherapy. This paper will focus on the recent advances and understanding of cancer testis antigens in sarcoma
and also clinical data of immunotherapeutic approaches in these diseases.
1.Introduction
Immunotherapy has recently had signiﬁcant well-publicized
successes. Placebo controlled, randomized Phase III trials
have demonstrated a survival beneﬁt for vaccine-based
therapy in follicular lymphoma [1] and prostate cancer [2].
Ipilimumab, an antibody that blocks the inhibitor of T-cell
activation, CTLA-4, has been shown to improve survival in
patients with metastatic melanoma [3].
Progress in the systemic treatment of sarcoma has
been frustratingly slow. Immunotherapy has long been
discussed as a promising method for the treatment of
patients with metastatic sarcoma [4, 5]. Sadly, despite a
number of ambitious early phase immunotherapy trials, no
immunological treatments have become part of standard
clinical management. However, because of signiﬁcant strides
in our understanding of cancer immunology and because
of progress in other disease types, immunotherapy remains
a source of hope that exciting new therapies are on the
horizon for patients with sarcoma. We now know that
many of the most promising targets for immunotherapy are
frequently expressed in certain sarcoma subtypes. Lessons
learned from other diseases, such as melanoma, can guide
a new generation of immunotherapy trials with the aim
of preventing recurrent disease in resected sarcoma and
improving the survival of patients with advanced disease.
Here we discuss some of the potential targets for im-
munotherapy trials with a focus on the cancer testis antigens
(CTAs) and their expression in individual sarcoma subtypes.
We also review prior trials of immunotherapy including
nonspeciﬁc immunomodulators, vaccines, and adoptive
immunotherapy.
2. Completed Immunotherapy Trials
Immunotherapies can be divided into the following three
categories: nonspeciﬁc immunomodulation, vaccines, and
adoptive cellular therapy. Nonspeciﬁc immunomodulation
induces antitumor immunity without exposing the patient
to a target molecule. By contrast, vaccines expose patients
to antigens in order to provoke an antitumor immune
response usually in the presence of adjuvant and occasionally
in combination with immunomodulation [3, 6]. Some of
these vaccines have been targeted to sarcoma-speciﬁc fusion
products such as SYT-SSX in synovial sarcoma, whereas
other vaccines are less antigen directed such as those that
haveusedirradiatedautologoustumorcells.Finally,adoptive
cellular therapy involves the ex vivo expansion of immune
eﬀector cells (often T cells and/or NK cells) from a patient
for later reinfusion. This may be nonspeciﬁc, as in the
case of leukocyte-activated killer cells or tumor-inﬁltrating2 Sarcoma
lymphocytes, or may use antigen-speciﬁc cultures ex vivo or
genetically engineered to have tumor-directed speciﬁcity.
3. Nonspeciﬁc Immunomodulation
Some of the ﬁrst trials demonstrating the potential of
immunotherapy in cancer used high-dose interleukin-2 (IL-
2) in patients with metastatic melanoma and renal cell
carcinoma. Six sarcoma patients were included in these early
high-dose IL-2 trials used in combination with leukocyte-
activated killer cells. None of these patients responded
[7]. More recently, however, high-dose IL-2 was given
in a pediatric population including several patients with
osteosarcoma [8]. In total, 10 pediatric patients with heavily
pretreated, progressive, or metastatic solid tumors were
treated with high-dose IL-2. The cohort included 4 patients
with osteosarcoma and 2 patients with Ewing’s sarcoma. Two
of the four osteosarcoma patients had complete responses
thatweredurablewithmedianfollowupof28months(range
11–36 months for the 10 patients treated on study). Given
that in long-term follow-up studies of adult patients with
metastatic solid tumors treated with high-dose IL-2, patients
who are disease-free 30 months following treatment are
considered extremely unlikely to relapse [7], this pediatric
study represents an encouraging ﬁnding that warrants more
investigation focused on osteosarcoma.
Muramyltripeptidephosphatidylethanolamine(MTP)is
a synthetic analogue of a bacterial cell well that has been
studied clinically as a nonspeciﬁc immune modulator. Early
studies demonstrated that peripheral blood mononuclear
cells taken from patients following treatment with liposomal
MTP demonstrated increased tumor cell killing in vitro
compared with baseline samples [9, 10]. Furthermore, the
drugwasassociatedwithincreasedserumlevelsofTNFalpha
and IL-6 [10].
The Children’s Oncology Group’s Intergroup-0133 stud-
ied MTP using a 2 × 2 design. In the ﬁrst randomization,
patients either received or did not receive ifosfamide with a
chemotherapy backbone of cisplatin, doxorubicin, and high-
dose methotrexate. In the second randomization, patients
either received or did not receive liposomal-MTP. Analysis of
this study has been complicated; the ﬁrst analysis published
in 2005 showed a trend towards improved outcomes for the
MTP-containing arm that was not statistically signiﬁcance.
With more mature followup, a 2008 report demonstrated a
statistically signiﬁcant improvement in overall survival with
a strengthening of the event-free survival trend for the MTP-
containing arm. A 2009 report in cancer suggested that
improvements in outcomes may also be seen in patients with
metastatic disease although this analysis was not powered to
demonstrate a statistically signiﬁcant beneﬁt in either event-
f r e eo ro v e r a l ls u r v i v a l[ 11–13]. To date, liposomal MTP has
not secured FDA approval but is available at a number of
centers for compassionate use.
Alpha interferon has also been used in several sarcoma
subtypes, particularly osteosarcoma, with varying success.
There have been case reports of responses to interferon
in osteosarcoma [14, 15] and complete responses in clear
cell sarcomas [16, 17]. From 1971 to 1990, 89 consecutive
patients with localized high-grade osteosarcoma received
adjuvant therapy with interferon-α. Between 1971 and 1984,
70 patients were treated with a dose of 3 × 106 IU once
a day for one month, and subsequently 3 times weekly for
further 17 months. Nineteen patients were treated between
1985 and 1990 with a dose of 3 × 106 IU daily, with
treatment extending for 2–5 years. With a median followup
of 12 years (range 2–16), the observed 10-year metastases-
free and sarcoma-speciﬁc survival rates were 39% and 43%,
respectively. Detailed toxicity data was not available for
the period following 1979, but excellent compliance with
treatment implies no major additional toxicity [18, 19].
Contrasting results have been observed by other investi-
gators. The German/Austrian cooperative study COSS-80
randomized 158 patients with localized osteosarcoma to
receive methotvexate and doxorubicin with either cisplatin
alone or the combination of bleomycin, cyclophosphamide,
and dactinomycin. Patients were also randomized to receive
or not receive 22 weeks of interferon-β. Interferon-β was
commenced at week 16, consisting of 2 injections weekly
for 2 weeks, then daily injections for 4 weeks and then
2 injections weekly for further 16 weeks. The dose of
interferon-β was 100,000U/kg. No signiﬁcant diﬀerence in
30-month continuous disease-free survival was observed
between patients treated with and without interferon-β
(77% versus 73%, resp.) [20]. The diﬀering results observed
in the Scandinavian and German/Austrian studies may be
due to the relatively low interferon dose and duration of
therapy in the COSS-80 trial. The current European and
American Osteosarcoma Study Group (EURAMOS 1) trial
randomizes patients with localized osteosarcoma, who have
had a good histological response to neoadjuvant chemother-
apy, to receive postoperative systemic therapy consisting of
methotrexate, doxorubicin, and cisplatin with or without
pegylated interferon α-2b. The pegylated preparation of
interferon α has an extended half life and consequently can
be administered less frequently with higher dose delivery.
The results of this large randomized trial will, it is hoped,
deﬁne the role of interferon in the adjuvant treatment of
osteosarcoma.
Ito and colleagues reported decreases in size of lung
metastases in 2 out of 3 osteosarcoma patients treated with
interferon. Edmonson et al. reported on a Phase II trial of
recombinant interferon α-2a in 20 patients with advanced
bonesarcomas,17ofwhomhadosteosarcoma.Partialtumor
regression was documented in 2 patients with osteosarcoma
and one with malignant ﬁbrous histiocytoma, for 1, 3, and 2
months, respectively. Three other patients had stable disease
(each for 2 months), but all other patients had disease
progression.
4.TargetedImmunotherapy
Potential targets for immunotherapy have been divided into
ﬁve categories: mutated, shared tumor speciﬁc, diﬀerenti-
ation antigens, overexpressed antigens, and viral antigens
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“Mutated” antigens involve a mutation in the cancer not
present in normal tissues, thus making the target inherently
speciﬁc.AnexampleofthisinsarcomaistheSYT-SSXfusion
protein. This epitopes from this mutant protein have been
targeted in two Phase I trials (described below).
“Shared tumor speciﬁc” antigens are frequently ex-
pressed by a number of malignancies but rarely are expressed
by normal tissue. This category includes the cancer testis
antigens (described below). These antigens are highly
immunogenic and are important for early development.
They are frequently seen in the developing embryo but are
not found in signiﬁcant quantities in adults except in the
testis and occasionally the placenta.
“Diﬀerentiation antigens” are antigens involved in the
normal diﬀerentiation of a speciﬁc tissue type. MART-1 is
an example of this type of antigen that has been successfully
targetedinmelanoma.Thisproteinisexpressedaspartofthe
normal diﬀerentiation of melanocytes and certain other cells
from neural crest tissue. This diﬀerentiation antigen appears
to be expressed in clear cell sarcoma as well [22].
“Overexpressed” targets are expressed in normal tissue
but greatly overexpressed in tumors. This category includes
HER2 which is frequently expressed in synovial sarcoma
[23]. Some of these overexpressed antigens have been
described as “universal antigens,” as they may be more uni-
formly expressed by tumors such as telomerase (hTERT) and
survivin; these antigens may be associated with tumorigenic
advantage thus targeting these antigens may circumvent the
potential for outgrowth of antigen-loss variants [24, 25].
Viral antigens from viruses such as EBV have been
shown to present immunogenic epitopes. This strategy may
be applicable to Kaposi’s sarcoma which is associated with
HHV8 [26].
4.1. Cancer Testis Antigens. As described above, the cancer
testis antigens (CTAs) are a group of proteins considered
to be some of the most exciting potential targets for
immunotherapy. Investigators have long sought to char-
acterize speciﬁc tumor-associated antigens that would be
considered “immunogenic,” that is, capable of inducing an
immune response. Pioneering work by Thierry Boon and
colleagues at the Ludwig Institute for Cancer Research in
Brussels uncovered distinct antigens recognized by cytotoxic
T lymphocytes (CTLs). This group ﬁrst described 4 distinct
antigens in mice (A, B, C, and D), two of which were
products of the same gene, P1A [27, 28]. Following on the
heels of this discovery, the Boon group identiﬁed the ﬁrst
human tumor-associated T-cell-deﬁned antigen, MAGE-1
(MelanomaAntigen-1,subsequentlyrenamedMAGE-A1)by
screening target cells transfected with the cDNA library of a
tumor line using autologous tumor reactive antigen-speciﬁc
CTL.
More T-cell-deﬁned antigens were discovered, and
MAGE-1 was eventually recognized to be part of a family of
MAGE antigens which represent a broader class of antigens
ultimatelydescribed byLloyd Oldas“cancer-testis”antigens.
These antigens have expression restricted to germline tissues,
placental trophoblasts, and a broad range of cancers. To date
there are more than 70 CT gene families, many of which are
being developed as T-cell targets for vaccine and adoptive
cellular therapy [29].
4.2. Cancer Testis Antigen Expression in Speciﬁc Sarcoma
Subtypes. Only a handful of articles have described can-
cer testis antigen expression in speciﬁc sarcoma subtypes.
Complicating matters is that while all cancer testis antigens
are by deﬁnition immunogenic, they are not all necessarily
immunogenic for all individuals. Each CTA has epitopes
described for at least one HLA type but many HLA types
are quite rare. Since the class I HLA type A∗02.01 is
relatively common, expressed by about half of the Caucasian
population, targeting A∗02.01 associated epitopes in pilot
immunotherapy trials for sarcoma is a reasonable approach.
Some of the commonly expressed cancer testis antigens, for
which A∗02.01 epitopes have been identiﬁed, are NY-ESO-
1, LAGE-1, PRAME, MAGE-A3, MAGE-A4, MAGE-A9, and
SSX-2.Theexpressionoftheseantigensinthemostcommon
s a r c o m as u b t y p e si si l l u s t r a t e di nT a b l e1.
Currently, there is more data available on the expression
of these antigens for synovial sarcoma than any other
sarcoma subtype. It is well documented that the majority
of these tumors express the cancer testis antigen NY-ESO-
1, particularly those with monophasic histology where it is
frequently expressed homogenously [30]. The biphasic type
also expresses NY-ESO-1 in the majority of cases, although
not always and occasionally these tumors may only express
NY-ESO-1 in one of the biphasic compartments. Synovial
sarcomas tend not to express MAGE-A1 or CT7, though
little is known about the prevalence of other CT antigens in
this histological subtype. One gene microarray study found
that all four cases of synovial sarcoma included in that
study expressed PRAME [31]. This study included 7 cases of
myxoid liposarcoma and 5 nonmyxoid. All the nonmyxoid
liposarcoma cases and 1 of the myxoid subtype expressed
PRAME. LAGE-1 was expressed in over 70% of myxoid
liposarcomas and in 60% of nonmyxoid liposarcomas [31].
One study by the Ludwig group in New York assessed
CT antigen expression for a number of diﬀerent sarcoma
subtypes and included 6 liposarcomas [32]. Three expressed
LAGE-1.
Less is known about leiomyosarcoma and it is possible
that uterine and nonuterine leiomyosarcoma have distinct
patterns of CT antigen expression. In the study by Ayyoub
et al., for example, four of six uterine leiomyosarcomas
examined expressed MAGE-A3, while only one of the seven
nonuterine leiomyosarcomas expressed MAGE-A3 [32].
Three of the six uterine leiomyosarcomas expressed NY-ESO
and 2 expressed LAGE-1. No nonuterine leiomyosarcomas
expressed NY-ESO and only 1 of 7 expressed LAGE-1.
Many leiomyosarcomas, particularly uterine leiomyosar-
comas, may express CTAs from the SSX family including
SSX-2 which has an A∗02.01 epitope. In the study of SSX
antigens by Ayyoub et al. 3 of 4 expressed SSX-2 [33].
Among the skeletal sarcomas, osteosarcoma is known
to express several CT antigens. One study of CT antigen
expression in pediatric solid tumors included 9 osteosar-
coma patients. All of these osteosarcoma samples expressed4 Sarcoma
Table 1: Selected CT antigen expression (all with A∗02.01 epitopes) in selected sarcomas.
Sarcoma subtype Reference Method NY-ESO-1 LAGE-1 PRAME MAGE-A3 MAGE-A4 MAGE-A9 SSX-2
MFH/pleomorphic spindle cell [32] RT-PCR 1/6 0/6 1/6 0/6
[33]R T - P C R 1 / 2
[31] Microarray 0/16 1/16 1/16
Liposarcoma [32] RT-PCR 2/2 1/2 1/2 2/2
[33]R T - P C R 1 / 2
Myxoid [31] Microarray 5/7 6/7 5/7
Nonmyxoid [31] Microarray 3/5 5/5 2/5
Leiomyosarcoma [31] Microarray 0/9 3/9 1/9
Uterine leiomyosarcoma [32] RT-PCR 3/5 2/5 3/5 4/5
[33]R T - P C R 3 / 4
Nonuterine leiomyosarcoma [32] RT-PCR 0/7 1/7 1/7 2/7
[32]R T - P C R 0 / 1
Synovial sarcoma [32] RT-PCR 2/2 1/2 1/2 2/2
[30] IHC 20/25
[31] Microarray 3/4 4/4 3/4
Skeletal sarcomas
Osteosarcoma [32] RT-PCR 0/1 0/1 0/1 0/1
[33]R T - P C R 0 / 1
[34] qRT-PCR 8/9 (NY-ESO + LAGE) 9/9 4/9
Ewings Sarcoma [34] qRT-PCR 0/18 (NY-ESO + LAGE) 5/18 4/18
Chondrosarcoma [32] RT-PCR 2/2 2/2 2/2 1/2
MAGE-A3 by real-time PCR and all but one expressed
LAGE-1/NY-ESO [34]. By contrast, few of the Ewing’s sar-
coma patients in that study expressed cancer testis antigens.
4.3. Vaccine-Based Trials. A number of small trials have
immunized patients against sarcoma achieving varying levels
of success using a variety of diﬀerent vaccines. Some of
these trials have targeted well-deﬁned antigens, others have
targeted tumor lysate. In one such trial, sarcoma patients
received an intradermal injection of irradiated autologous
tumor cells grown in culture to vaccinate against antigens
that would be released from these dying cells. Almost
all of the patients also received either interferon gamma
or GM-CSF as an adjuvant. An immune response was
demonstrated using a delayed-type hypersensitivity (DTH)
skin test against autologous tumor which converted from
negative to positive in 8 of 16 evaluable patients. Median
survival was 16.6 months among patients who were DTH
responders compared with 8.2 months in those who were
nonresponders. This was a statistically signiﬁcant diﬀerence
that is hypothesis generating but is of questionable causality.
There were no objective responses among the study partici-
pants with measurable disease. Of note, the study included
one patient with resected pulmonary metastatic disease
(without measurable disease at the time of vaccination) who
was disease-free over 3 years following vaccination [6].
One vaccine trial gave intradermal injections of dendritic
cells pulsed with autologous tumor lysate [35]. Ten pediatric
patients were treated; one patient with ﬁbrosarcoma had
a partial response to the treatment which included the
complete regression of several sizable pulmonary sites of
metastatic disease.
The largest dendritic cell vaccine trial to date for the
treatment of patients with sarcoma targeted recurrent or
metastatic Ewing’s sarcoma family tumors or alveolar rhab-
domyosarcoma having a t(2;13) or t(11;22) translocation.
Patients were treated with dendritic cells pulsed with tumor-
speciﬁc peptides derived from the fusion proteins as a
consolidative therapy after patients achieved a complete
remission. Improved survival was seen in the group of
patients receiving vaccination compared with those under-
going leukapheresis but not receiving vaccination. However,
this was a nonrandomized study in which patients not
receiving vaccination were more likely to have progressive
disease or declining performance status [36]. In the Phase
I trial of these vaccines 16 patients with bulky metastatic
disease were treated, one patient had a mixed response and
three patients had stabilization of disease [37].
In the posttransplant setting, a dendritic cell vaccine
trial was administered to 5 children with residual tumors
following autologous transplantation [38]. Three patients
received dendritic cells pulsed with tumor lysate. Two
patients received dendritic cells, pulsed with three synthetic
tumor-speciﬁc peptides related to either the SYT-SSX2
translocation sometimes seen in synovial sarcoma or the
EWS-FLI-1 fusion gene often seen in Ewing’s sarcoma. One
patient had a complete response that was durable for over
77 months and was ongoing at the time of the report. This
was the only patient with Ewing’s sarcoma receiving DCs
pulsedbyEWS-FLI-1-related synthetic peptides andsuggestsSarcoma 5
that these peptides may be worthy of further study. Two
other patients had stabilization of disease but ultimately
progressed.
Several studies have used vaccines of peptide alone. One
trial focused on the study drug 105AD7, a vaccineagainst
the complement regulatory protein CD55 frequently over-
expressed in osteosarcoma, was able to induce cytokine
production and antibody production in patients although
clinical response was modest [39, 40].
A peptide encompassing the SYT-SSX fusion region of
the gene resulting from the t(X;18) translocation has been
used to vaccinate six HLA-A∗24.02 positive patients. The
peptide vaccine succeeded in generating peptide-speciﬁc
CTLs that were successfully detected from four patients
following vaccination although all patients had negative
DTH skin testing. None of the patients experienced an
objective clinical response although one patient’s disease
stabilized [41]. The same group has produced interesting in
vitrodata showing that while CTL generated to the wild-type
peptide killed tumor relatively poorly (the peptide used for
the vaccine), a one amino acid substituted K9I peptide (also
an A∗2402 associated epitope) produced CTL which killed
tumor far more eﬀectively [42].
There is an on-going randomized placebo controlled
multicentered Phase II trial of a trivalent peptide vaccine
to the gangliosides GD2, GD3, and GM2 in patients with
stage IV sarcoma who have no evidence of disease following
resection. These gangliosides are thought to play a role in
cell adhesion and cell-cell interactions. They are usually
expressed by melanomas and also may be expressed by some
sarcomas [43, 44], and in Ewing’s and osteosarcoma in
particular [45, 46]. Moreover, soft tissue sarcoma patients
frequently develop an antibody response to GD2 compared
with healthy controls [47]. However, the promise of this
vaccine must be tempered by the fact that a randomized trial
in melanoma failed to demonstrate improvement in patient-
related outcome measures [48].
4.4. Adoptive Immunotherapy. In adoptive immunotherapy,
patients are treated with autologous lymphocytes taken from
a patient and expanded ex vivo. Some of the most impres-
sive clinical results have come from studies using tumor-
inﬁltrating lymphocytes (TILs) in patients with melanoma.
In these studies, tumor is taken from a patient and the
lymphocytes are separated and expanded ex vivo and then
reinfused following patient lymphodepleting conditioning.
The most promising results were those patients whose con-
dition involved an intensive regimen requiring autologous
transplant with total body irradiation, cyclophosphamide
and ﬂudarabine conditioning followed by high-dose IL-2
postinfusion. The median survival for metastatic melanoma
is less than a year, however, a 2-year survival rate of over 40%
has been reported using this adoptive immunotherapeutic
approach. It should be noted that considerable toxicity
has been reported in these trials [49]. Though some early
work did seem to demonstrate that TIL could often be
grown in culture from patients with sarcoma, although
with lower yield compared with other tumor types, little
f o l l o w - u pw o r kh a sb e e nd o n e[ 50, 51]. However, given
that a number of sarcoma subtypes do often have tumor
inﬁltrating lymphocytes (unpublished data), this may be an
area deserving further study.
Furthermore, as more has been learned about the poten-
tial targets for adoptive immunotherapy, greater interest has
been given to developing T cells targeted towards speciﬁc
antigens either by isolating rare tumor targeted cells from a
patient’s peripheral blood or by genetically modifying T cells
to target a speciﬁc antigen. Given the frequent expression of
CT antigens in certain sarcoma subtypes, sarcoma may be
an ideal target for antigen-speciﬁc adoptive immunotherapy.
The Rosenberg group at the NCI has begun treating synovial
sarcoma patients with lymphocytes using a transduced T-cell
receptor speciﬁc for NY-ESO-1.
5. Conclusion
While past attempts to use immunotherapy have failed to
dramatically shift the paradigm of care for the treatment of
patients with sarcoma, a great opportunity exists to shape
the future. Nonspeciﬁc immunomodulation with the use of
muramyl tripeptide phosphatidylethanolamine in resected
osteosarcoma has shown a signiﬁcant survival beneﬁt. Other
immune approaches have shown signals of potential in
isolatedpatientswithdramaticresponsestoimmunotherapy.
A greater understanding of the immune system and the
ability to harness more potent approaches to utilize the
ability of the immune system to ﬁght cancer could result
in advances in the treatment of sarcoma. There remains
a need for novel eﬀective therapy in advanced soft tissue
sarcoma, particularly in chemoresistant subtypes where no
conventional systemic therapy is available. Emphasis on
the immunological characteristics of individual sarcoma
subtypes and the consequent tailoring of therapy could
increase the therapeutic options available. The exact role
of immunotherapy in sarcoma is yet to be delineated. It is
hoped with well-designed, multiinstitutional clinical trials
that this treatment approach will result in improvements in
survival in this challenging group of diseases.
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